Shareholder Alert: The Ademi Firm Investigates Whether scPharmaceuticals Inc. Is Obtaining a Fair Price for Its Public Shareholders

MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating scPharmaceuticals (NASDAQ: SCPH) for possible breaches of fiduciary duty and other violations of law in its transaction with MannKind. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. Shareholders of scPharmaceuticals will receive $5.35 per share in cash plus contingent value rights worth up to $1.0